Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc. (2017)
green
· 22 citation events
across 3 courts.
Showing the 4 strongest citers on record
(one row per citing case, strongest signal kept).
Treatment trajectory · 2018 → 2026 · click a year to view the case as of then
201820222026
Sort:
By significance ·
Most recent
Id. at 519 n.13 (“The Court comes to this conclusion [of no invalidity] exclusive- ly on the basis of the record developed in this litigation.”); id. at 521 (“Based upon the record in this litigation, the Court sees no reason to deviate from this finding” in SUPERNUS PHARMAS., INC. v. TWI PHARMAS., INC. 7 Actavis “that the term ‘homogeneous matrix’ had ade- quate written description.”).
green
Fairhaven Health LLC v. BioOrigyn LLC (2023)
Cir. 2013) (After trial, Court found that, given differences in particle size specification between compared products, a Canadian product was not likely to be representative of the 25 accused product), to argue for striking references to test data, while Defendant cites Supernus Pharms., Inc. v. TWi Pharms., Inc., 265 F. Supp. 3d 490, 509 (D.N.J. 2017), aff’d, 747 F. App’x 852 (Fed.
green
SUPERNUS PHARMACEUTICALS, INC. v. RICONPHARMA LLC (2022)
(Supernus Br. 9.) In both Activis and TWi, Judge Bumb construed the term “homogeneous matrix” as “a matrix in which the ingredients or constituents are uniformly dispersed.” Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc., 265 F. Supp. 3d 490, 498 (2017).
See Supernus Pharm., Inc. v. TWi Pharm., Inc., 265 F. Supp. 3d 490, 517 (D.N.J. 2017), aff’d, 747 F. App’x 852 (Fed.